Boston Life Sciences, Inc to Present at the BIOInvestor Forum

The BIO InvestorForum is sponsored by the Biotechnology IndustryOrganization and features company presentations, panel discussions andkeynote speeches on topics such as clinical strategy, productdevelopment and the shifting regulatory landscape.

The webcast will be available on the Boston Life Sciences, Inc.website at http://www.bostonlifesciences.com. If you are unable tolisten to the live webcast, it will be archived on the BLSI websitethrough November 2, 2005.

About Boston Life Sciences

Boston Life Sciences, Inc. (BLSI) is engaged in the research andclinical development of diagnostic and therapeutic products forcentral nervous system (CNS) disorders. ALTROPANE molecular imagingagent is in Phase III clinical trials for the diagnosis ofParkinsonian Syndrome (PS) and a Phase II clinical trial for thediagnosis of Attention Deficit Hyperactivity Disorder (ADHD). TheCompany's research and pre-clinical CNS programs include Inosine forthe treatment of stroke, O-1369 for the treatment of Parkinson'sdisease and FLUORATEC(TM), a second generation molecular imagingagent, for PS and ADHD. BLSI's current research collaborations includeHarvard Medical School, Children's Hospital of Boston and theUniversity of Massachusetts-Worcester.

The foregoing release contains certain forward-looking statementswithin the meaning of the Private Securities Litigation Reform Act of1995. Forward-looking statements include statements regarding BostonLife Sciences' expectations, beliefs, intentions or strategiesregarding the future and can be identified by terminology such as"anticipate," "believe," "could," "estimate," "expect," "intend," "isplanned," "may," "should," "will," "will enable," "would be expected,""look forward," "may provide," "would" or similar terms, variations ofsuch terms or the negative of those terms. Such forward-lookingstatements involve known and unknown risks, uncertainties and otherfactors including those risks, uncertainties and factors referred toin the Company's Quarterly Report on form 10-Q for the quarter endedJune 30, 2005, filed with the Securities and Exchange Commission underthe section "Risk Factors," as well as other documents that may befiled by Boston Life Sciences from time to time with the Securitiesand Exchange Commission. As a result of such risks, uncertainties andfactors, the Company's actual results may differ materially from anyfuture results, performance or achievements discussed in or implied bythe forward-looking statements contained herein. Boston Life Sciences,Inc. is providing the information in this press release as of thisdate and does not undertakes any obligation to update anyforward-looking statements contained in this press release as a resultof new information, future events or otherwise.

ALTROPANE is a registered trademark and FLUORATEC is a trademarkof Boston Life Sciences, Inc.